DiaSys Corporation Announces Ten New Point of Care Rapid Test Product Introductions.WATERBURY, Conn. -- DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX) a global healthcare products company announced today the introduction of ten new point of care rapid test products for worldwide distribution. These new products consist of four cardiac markers, three cancer markers, two infectious disease tests and a Thyroid test. These new products will be listed on the company's website and sold through DiaSys Corporation's worldwide distribution network. The four cardiac markers are Troponin I, CK-MB CK-MB Creatine phosphokinase MB isoenzyme Cardiology A CK isoenzyme usually ↑ in acute MI; CK-MB may be ↑ in muscular dystrophy, polymyositis, myoglobinuria, malignancy–eg, lung CA. Cf Troponin I, Troponin T. , Myoglobin myoglobin (mī'əglō`bĭn), protein molecule isolated from the cells of vertebrate skeletal muscle that is both a structural and functional relative of hemoglobin, the oxygen-transport protein of the blood of higher animals. , and CRP C-reactive protein (CRP) A protein present in blood serum in various abnormal states, like inflammation. Mentioned in: Pelvic Inflammatory Disease CRP, n.pr See C-reactive protein. . The three cancer markers are Id1, HMGA2 and Alpha Fetoprotein. The two infectious disease tests are a Malaria Combo Test and Dengue IgG and IgM. The Thyroid test is a Neonatal TSH TSH thyroid-stimulating hormone; see thyrotropin. TSH abbr. thyroid-stimulating hormone Thyroid-stimulating hormone (TSH) . Each of these tests will be sold in a point of care rapid test configuration. Gregory Witchel, Chief Executive Officer of DiaSys Corporation stated, "These new product offerings from DiaSys are manufactured in the United States under GMP and ISO compliance and are of the highest quality. We intend to build out our current product offerings to compliment our existing line of products and to leverage our worldwide distribution capabilities." DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. 
Yosbel Rodriguez Gomez (Member): Error en la traduccion del prospecto de reactivos de CK CKMB 10/6/2009 10:21 AM
existe un error en la traduccion de ingles a español en el prospecto de CK CKMB en cuanto al rango de sospecha de ima por favor revisar y corregir la informacion |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion